Biotie Therapies - Company Announcement

Biotie: Selincro launched in the United Kingdom

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE     6 May 2013 at 5.35 p.m.

Biotie: Selincro launched in the United Kingdom

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched
Selincro in the United Kingdom. According to the terms of the license agreement
between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone
payment of EUR 2 million related to the UK launch. Biotie will potentially
contribute to Lundbeck towards any required post approval commitment studies.
These contributions are not expected to be significant in 2013.

Lundbeck will continue the rollout of Selincro in additional European markets
through 2013 and into 2014.

Turku, 6 May 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa President and CEO
tel. +358 2274 8900, email: timo.veromaa@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd

Main Media

ABOUT SELINCRO (nalmefene):

Selincro is indicated for the reduction of alcohol consumption in adult patients
with alcohol dependence who have a high drinking risk level (>60 g/day for men,>40 g/day for women) without physical withdrawal symptoms and who do not require
immediate detoxification. Selincro should be prescribed in conjunction with
continuous psychosocial support focused on treatment adherence and the reduction
of alcohol consumption. Treatment should be initiated only in patients who
continue to have a high drinking risk level two weeks after an initial
assessment. Selincro is to be taken as-needed; that is, on each day the patient
perceives a risk of drinking alcohol, one tablet should be taken, preferably
1-2 hours prior to the anticipated time of drinking.

Biotie has licensed global rights to Selincro to Lundbeck. Under the terms of
the agreement, Biotie is eligible for up to EUR 89 million in upfront and
milestone payments plus royalties on sales of Selincro. Upon payment of the UK
launch milestone, Biotie will have received EUR 14 million of such milestone
payments from Lundbeck. Further payments of up to EUR 2 million are expected on
commercial launch of Selincro in each of France, Germany, Italy and Spain, and
further potential milestone payments on launches in certain other markets and if
the product reaches certain predetermined sales. Lundbeck is responsible for the
registration, manufacturing and marketing of the product.

ABOUT BIOTIE

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post-traumatic stress disorder), and inflammatory and fibrotic
liver disease. The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie's most advanced product, Selincro (nalmefene), licensed to H. Lundbeck
A/S, has on 28 February 2013 received European marketing authorization for the
reduction of alcohol consumption in adult patients with alcohol dependence who
have a high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which is transitioning
into Phase 3 development for Parkinson's disease. Biotie shares are listed on
NASDAQ OMX Helsinki Ltd.


[HUG#1699584]